Economic burden of patients with advanced non-small-cell lung cancer receiving nivolumab versus chemotherapy in China

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. SEER Incidence Data, 1975–2016. https://seer.cancer.gov/data/
  Google Scholar
• 2. Chen W, Zheng R, Baade PD et al. Cancer statistics in China, 2015. CA Cancer J. Clin. 66(2), 115–132 (2016).
  MedlineGoogle Scholar
• 3. Proto C, Ferrara R, Signorelli D et al. Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out. Cancer Treat. Rev. 75, 39–51 (2019).
  Medline CASGoogle Scholar
• 4. Arunachalam A, Li H, Bittoni MA et al. Real-world treatment patterns, overall survival, and occurrence and costs of adverse events associated with second-line therapies for Medicare patients with advanced non-small-cell lung cancer. Clin. Lung Cancer 19(5), e783–e799 (2018). •• This restrospective cohort study identifies 4033 patients with advanced non-small-cell lung cancer (NSCLC) who were treated with second-line therapy. In the real world, second-line therapy (not including the immunotherapies) illustrates the high cost.
  MedlineGoogle Scholar
• 5. Wood R, Taylor-Stokes G. Cost burden associated with advanced non-small cell lung cancer in Europe and influence of disease stage. BMC Cancer 19(1), 214–214 (2019).
  MedlineGoogle Scholar
• 6. Andreas S, Chouaid C, Danson S et al. Economic burden of resected (stage IB–IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: a retrospective observational study (LuCaBIS). Lung Cancer 124, 298–309 (2018). • Describes the burden of illness of patients with resected stage IB–IIIA NSCLC in the UK, France and Germany. NSCLC takes large annual national costs, especially during its progression.
  MedlineGoogle Scholar
• 7. Garrison LP Jr, Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value Health 10(5), 326–335 (2007). • Real world data were important for decision making but also had limitations.
  MedlineGoogle Scholar
• 8. Liu Q, Luo X, Peng L et al. Nivolumab versus docetaxel for previously treated advanced non-small cell lung cancer in China: a cost–effectiveness analysis. Clin. Drug Investig. 40(2), 129–137 (2020).
  Medline CASGoogle Scholar
• 9. Marine S, Stéphane R, Nicolas P et al. cost–effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in France. J. Med. Econ. doi:10.1080/13696998.2020.1718156 1–10 (2020) (Epub ahead of print).
  MedlineGoogle Scholar
• 10. Boone NW, Van Bodegraven AA. Less is more: a cost benefit analysis of a changed posology for nivolumab. Eur. J. Clin. Pharmacol. doi:10.1007/s00228-020-02839-7 (2020) (Epub ahead of print).
  MedlineGoogle Scholar
• 11. Giuliani J, Bonetti A. Financial toxicity and non-small-cell lung cancer treatment: the optimization in the choice of immune check point inhibitors. Anticancer Res. 39(7), 3961–3965 (2019).
  Medline CASGoogle Scholar
• 12. Verma V, Sprave T, Haque W et al. A systematic review of the cost and cost–effectiveness studies of immune checkpoint inhibitors. J. Immunother. Cancer 6(1), 128–128 (2018).
  MedlineGoogle Scholar
• 13. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373(17), 1627–1639 (2015). •• Nivolumab shows its benefit for overall survival compared with docetaxel among patients with advanced nonsquamous NSCLC in a Phase III clinical trial, CheckMate 057.
  Medline CASGoogle Scholar
• 14. Horn L, Spigel DR, Vokes EE et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, Phase III trials (CheckMate 017 and CheckMate 057). J. Clin. Oncol. 35(35), 3924–3933 (2017). • A report for the 2-year outcome for these two clinical trials: CheckMate 017 and CheckMate 057.
  Medline CASGoogle Scholar
• 15. Davies J, Patel M, Gridelli C, De Marinis F, Waterkamp D, Mccusker ME. Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: a systematic review of recently published studies. PLoS ONE 12(4), e0175679–e0175679 (2017).
  MedlineGoogle Scholar
• 16. Wu Y-L, Lu S, Cheng Y et al. Nivolumab versus docetaxel in a predominantly chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized Phase iii clinical trial. J. Thorac. Oncol. 14(5), 867–875 (2019).
  Medline CASGoogle Scholar
• 17. Areses Manrique MC, Mosquera Martínez J, García González J et al. Real world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician lung cancer group clinical experience. Transl. Lung Cancer Res. 7(3), 404–415 (2018). •• Another real-world data analysis for nivolumab in a Galician group, emphasizing the clinical outcome rather than disease burden.
  MedlineGoogle Scholar
• 18. Da Veiga CRP, Da Veiga CP, Drummond-Lage AP. Concern over cost of and access to cancer treatments: a meta-narrative review of nivolumab and pembrolizumab studies. Crit. Rev. Oncol. Hematol. 129, 133–145 (2018).
  MedlineGoogle Scholar
• 19. Kong J, Xu F, He M, Chen K, Qian B. The incidence of lung cancer by histological type: a population-based study in Tianjin, China during 1981–2005. Respirology 19(8), 1222–1228 (2014).
  MedlineGoogle Scholar
• 20. Zhang X, Wu L, Xu Y et al. Trends in the incidence rate of lung cancer by histological type and gender in Sichuan, China, 1995–2015: a single-center retrospective study. Thoracic Cancer 9(5), 532–541 (2018).
  Medline CASGoogle Scholar